Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Facing the challenge of viral mutations in the age of pandemic: Developing highly potent, broad-spectrum, and safe COVID-19 vaccines and therapeutics.

Clinical and translational medicine - 1 Jan 2021

Su Shan, Wang Qian, Jiang Shibo

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to COVID-19
Share to COVID-19 Vaccines
Share to Mutation
Share to Pandemics

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to SARS-CoV-2

Source

Open in PubMed Open full text

Identifiers

PMID: 33463059
DOI: 10.1002/ctm2.284
PMCID: PMC7803365

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Facing the challenge of viral mutations in the age of pandemic: Developing highly potent, broad-spectrum, and safe COVID-19 vaccines and therapeutics.PMID 33463059Read ↗

COVID-19: comprehensive review on mutations and current vaccines.Semantic proximity Read ↗

Variant-proof vaccines - invest now for the next pandemic.Semantic proximity Read ↗

COVID-19 one year into the pandemic: from genetics and genomics to therapy, vaccination, and policy.Semantic proximity Read ↗

Viruses, variants and vaccines.Semantic proximity Read ↗

Immediate need for next-generation and mutation-proof vaccine to protect against current emerging Omicron sublineages and future SARS-CoV-2 variants: An urgent call for researchers and vaccine companies – CorrespondenceSemantic proximity Read ↗

COVID-19: A state of art on immunological responses, mutations, and treatment modalities in riposte.Semantic proximity Read ↗

A comprehensive review on efficient approaches for combating coronaviruses.Semantic proximity Read ↗

A painful lesson from the COVID-19 pandemic: the need for broad-spectrum, host-directed antiviralsSemantic proximity Read ↗

SARS-CoV-2 Vaccines and the Growing Threat of Viral Variants.Semantic proximity Read ↗

COVID-19: Challenges of Viral VariantsSemantic proximity Read ↗

First COVID-19 DNA vaccine approved, others in hot pursuitSemantic proximity Read ↗

SARS-CoV-2 mutations, vaccines, and immunity: implication of variants of concern.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.